1: Kii I, Hirahara-Owada S, Yamaguchi M, Niwa T, Koike Y, Sonamoto R, Ito H, Takahashi K, Yokoyama C, Hayashi T, Hosoya T, Watanabe Y. Quantification of receptor activation by oxytocin and vasopressin in endocytosis-coupled bioluminescence reduction assay using nanoKAZ. Anal Biochem. 2018 May 15;549:174-183. doi: 10.1016/j.ab.2018.04.001. Epub 2018 Apr 5. PubMed PMID: 29627593. 2: Abu Jhaisha S, Widowati EW, Kii I, Sonamoto R, Knapp S, Papadopoulos C, Becker W. DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain. Sci Rep. 2017 Jul 25;7(1):6420. doi: 10.1038/s41598-017-06874-w. PubMed PMID: 28743892; PubMed Central PMCID: PMC5526990. 3: Kii I, Sumida Y, Goto T, Sonamoto R, Okuno Y, Yoshida S, Kato-Sumida T, Koike Y, Abe M, Nonaka Y, Ikura T, Ito N, Shibuya H, Hosoya T, Hagiwara M. Selective inhibition of the kinase DYRK1A by targeting its folding process. Nat Commun. 2016 Apr 22;7:11391. doi: 10.1038/ncomms11391. PubMed PMID: 27102360; PubMed Central PMCID: PMC4844702. 4: Sonamoto R, Kii I, Koike Y, Sumida Y, Kato-Sumida T, Okuno Y, Hosoya T, Hagiwara M. Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ. Sci Rep. 2015 Aug 3;5:12728. doi: 10.1038/srep12728. PubMed PMID: 26234946; PubMed Central PMCID: PMC4522657. 5: Masaki S, Kii I, Sumida Y, Kato-Sumida T, Ogawa Y, Ito N, Nakamura M, Sonamoto R, Kataoka N, Hosoya T, Hagiwara M. Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis. Bioorg Med Chem. 2015 Aug 1;23(15):4434-41. doi: 10.1016/j.bmc.2015.06.018. Epub 2015 Jun 14. PubMed PMID: 26145823.